Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

<p>– New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile – – Mechanistic mouse data show SNS-101 drives tumor macrophages to adopt an immunostimulatory, anti-tumor phenotype – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/sensei-biotherapeutics-presents-new-preclinical-data-reinforcing-sns-101-pharmacokinetic-profile-safety-characteristics-and-mechanism-of-action-at-the-seventh-cri-enci-aacr-international-cancer-immun/">Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>